The future of CNS drug development: signs of real progress
Drug Target Review
JULY 21, 2025
PROTACs are larger than traditional small-molecule inhibitors, so challenges arise in permeating the BBB, but they can target proteins previously considered ‘undruggable’. Targeted protein degraders can easily cause off-target toxicity.
Let's personalize your content